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PMS32 ASSESSMENT OF THE TOTAL DIRECT MEDICAL COST OF PATIENTS IN SECOND-LINE TNF INHIBITOR THERAPY AND OF THE RESPECT OF CLINICAL PRACTICE RECOMMENDATIONS
Launois R 1 , Letellier M 2 , Maunoury F 3 , Boissier MC 4 , Florentin V 5 1 REES France, Paris, Paris, France, 2 ALCIMED, Paris, Paris, France, 3 STATESIA, Le Mans, France, 4 APHP Paris, Bobigny, Ile de France, France, 5 Roche, Neuilly sur Seine, France OBJECTIVES: To establish the total direct medical cost of patients in second-line TNF a therapy from the French heath care system perspective. METHODS: A multicentre observational study was conducted, recruiting patients treated since at least four months by a second TNF a therapy. The sample represented was assessed through the comparison of the regional allocation of inclusions to the regional allocation of TNF a prescriptions issued from a national panel. Inpatient and outpatient consumptions were collected retrospectively, for the preceding four months. Respect of clinical practice recommendations was assessed through the analysis of administration frequencies and posologies. RESULTS: Fifty-nine hospital centres participated in the study, including 277 patients. The sample could be considered as representative as the correlation between the regional activity in terms of TNF a prescriptions and the number of included patients per region was high (r 0.88). The resulting total annual direct medical cost equalled a16,000 per patient. Respectively 43, 132, and 102 patients were included in the INF, ETA and ADA groups. Two patients treated by INF received more than the expected number of administrations, whereas 8 others had a higher dosage than that recommended. Respectively 11.4% and 24.5% of patients treated by ETA and ADA also received more administrations than expected during the 4 months of treatment. CONCLUSIONS: This representative study stated that hospitalisation costs represented 92% of the total direct medical costs of patients treated by a second-line TNF a therapy, reaching a16,000 per patient and per year. In the absence of a specific market authorisation in the indication, TNF a therapies are prescribed, but the clinical practice recommendations are not always respected.
PMS33 COST-BENEFIT ANALYSIS OF MANAGEMENT STRATEGIES TO REDUCE ROAD TRAFFIC INJURIES
Srijariya W, Riewpaiboon A, Chaikledkaew U, Pongcharoensuk P Faculty of Pharmacy Mahidol University, Ratchathewi, Bangkok, Thailand OBJECTIVES: to examine the cost-benefit of management strategies for reducing road traffic injuries. METHODS: The study was a cross-sectional analysis of secondary data retrieved from the Injury Surveillance (IS) in the fiscal year 2004 to 2006. The sample consisted of all traffic accidental patients who received hospital emergency services. The two dependent variables used were direct medical cost and death, multiple linear regression models and binary logistic regression models were constructed. The outputs of management strategies: non-use of crash helmets and drunk driving were explained by using Monte Carlo technique. RESULTS: The study covered 12,651 patients. For the regression analysis, statistically significant predictors were composed of sex, age, drunk driving, non-use of crash helmets, accidental timing, victim and severity (adjusted R 2 0.60). For the binary logistic regression analysis, odd-ratio of the causes of death of non-use of safety equipments (helmet and seatbelt) and drunk driving were 3.56 (CI 2.62-4.85) and 1.24 (CI 1.01-1.53) respectively. The direct medical cost arrived at from using the regression model when using law enforcement with 50 percent succession of both strategies was THB20,983,413.59. Compare with the current situation, it was THB26,709,449.76 (21.44% save). In the same way, the net benefit gain from these enforcement was THB512, 894, 977.48. (58.44% save) . Nevertheless, changing each assumption of the successful management strategies from 10% to 50%, the sensitivity analysis shows the range of saving from 24.67% to 58.44% and the benefit to cost ratio was 10.81. CONCLUSIONS: These findings show the scenario to reduce traffic injury, the law enforcement strategies for using safety equipment and reduce the number drunk driving is a useful management tool to reduce cost of illness nearly three-quarters of the damages from road traffic injuries.
PMS35 COST-EFFECTIVENESS OF BIOLOGIC THERAPEUTIC SEQUENCES FOR RHEUMATOID ARTHRITIS IN THE UK
Emery P 1 , Taylor P 2 , Isaacs JD 3 , Drost P 4 , Dupont D 4 , Beresniak A 5 1 Leeds General Infirmary, Leeds, UK, 2 Imperial College London, London, UK, 3 Newcastle University, Newcastle Upon Tyne, UK, 4 Bristol-Myers Squibb International Corporation, Braine l'Alleud, Belgium, 5 Data Mining International, Geneva, Switzerland OBJECTIVES: Biologic agents are commonly used sequentially to treat moderate to severe rheumatoid arthritis (RA). In absence of clinical trials comparing biologic strategies, simulation models are useful to inform decisions. The objective is to assess, using the NHS perspective, the cost-effectiveness of biologic strategies in patients with an insufficient response (IR) to at least 1 anti-TNF agent. METHODS: Simulation models were developed to assess four strategies of different biologic agents over 2 years. Assuming an IR to the 1st anti-TNF agent, Sequence 1 included etanercept-abatacept-adalimumab and Sequence 2 etanercept-rituximab-adalimumab. Assuming an IR to 2 anti-TNF agents, Sequence 3 included etanercept-adalimumababatacept and Sequence 4 etanercept-adalimumab-infliximab. Effectiveness data was derived from published evidence based on achieving a low disease activity state (LDAS). Switch occurred at each 6 months in case of an IR to the previous agent. UK direct medical costs and biologic drug costs were used. Extensive probabilistic sensitivity analyses were performed. RESULTS: There were 6-month medical costs (excluding biologic drug costs) were estimated at £1047 (Standard Deviation [SD] 332) for managing patients in LDAS and at £2650 (SD 963) for moderate-to-high disease activity. Over 2 years, Sequence 1 appeared more efficacious (92 days in LDAS) versus Sequence 2 (82 days in LDAS,) with cost-effectiveness ratios of £281/day in LDAS vs. £289/day in LDAS, respectively. Sequence 3 appeared more efficacious (43 days in LDAS or) vs. Sequence 4 (32 days in LDAS), with cost-effectiveness ratios of £603/day in LDAS vs. £809/day in LDAS, respectively. CONCLUSIONS: Medical costs associated with moderate-to-high disease activity are estimated to be 2.5 times higher than for LDAS, suggesting that efficacious treatment strategies contribute to reducing use of health care services. The results of this simulation model suggest that, for achieving LDAS, sequences including abatacept after an IR to at least 1 anti-TNF agent appear more cost-effective than similar sequences including rtx or cycled anti-TNF agents.
PMS36 COST-EFFECTIVENESS OF ZOLEDRONIC ACID ONCE-YEARLY INFUSION IN THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROTIC FRACTURES BASED ON COMPLIANCE AND NUMBER NEEDED TO TREAT APPROACH IN THE TURKISH HEALTH CARE SETTING
Pala M, Göl D Novartis Pharma, Istanbul, Turkey OBJECTIVES: Several studies have demonstrated that compliant and long-term use of bisphosphonates is necessary to realize full benefits of treatment. In particular, a progressive relation between compliance (medication possession ratio above 80%) and fracture risk reduction has been found (Siris, Mayo Clin Proc 2006; 81:1013-22 and Penning, Osteoporos Int 2008; 19:511-17) . Taking into account patient compliance, we compared the effectiveness and costs of zoledronic acid (ZOL) versus weekly alendronate & risedronate and monthly ibandronate therapies over 3 years in the prevention of postmenopausal osteoporotic fractures from the NHS perspective of Turkey, using Number Needed to Treat (NNT) approach. METHODS: NNT values (1 / (placebo fracture risk -treatment fracture risk) for vertebral (VF), non-vertebral (NVF) and hip fractures (HF) were derived as a function of fracture risks and compliance rates associated with each therapy. Both drug costs and efficacies were adjusted to compliance rates. Relative risks and placebo incidences of each fracture type were obtained from the clinical trials, meta-analyses from NICE reviews, and costs were gathered from local price database. Annual compliance rates were taken from the literature (Willemijn, Cur Med Res Opin 2008; 24:3217-22) . RESULTS: Compared to each oral bisphosphonate (OB), ZOL generated the lowest clinical NNTs for all fracture sites. Under conservative compliant patient rate of 50% for weekly and 75% for monthly OBs, cost of treatment to prevent one fracture in 3 years was a30,625 (VF) and a160,400 (HF) for ZOL; a76,800 (VF) and a272,900 (HF) for branded alendronate; a75,825a (VF) and a269,325a (HF) for generic alendronate; a170,250 (VF) and a783,400 (HF) for risedronate; and a65,725 (VF) for ibandronate. Sensitivity analyses were performed. CONCLUSIONS: In the Turkish setting, compared to all OBs once-yearly administered ZOL was dominantly the most cost-effective treatment regardless of fracture type upto a level of 90% compliance with oral therapies.
PMS37 DOES GENERIC ALENDRONATE REALLY SAVE MONEY IN THE TREATMENT OF OSTEOPOROSIS GIVEN SUB-OPTIMAL REAL LIFE COMPLIANCE? AN EXAMPLE FROM THE DANISH SETTING
Ariely R 1 , Tambour M 2 , Olson M 3 1 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2 Novartis Sverige AB, Taby, Sweden, 3 Novartis Pharma AG, Basel, Switzerland OBJECTIVES: To evaluate the cost effectiveness of zoledronic acid 5 mg once yearly compared to generic alendronate in postmenopausal patients with osteoporosis. METHODS: A cost effectiveness model, based on the model used in the NICE appraisals of the cost effectiveness of osteoporosis treatments in postmenopausal women at increased risk of fracture, was adapted to the Danish setting. Lifetime costs and quality adjusted life years (QALYs) were calculated assuming five years of treatment. Relative risks of fracture protection were obtained from the HORIZON-PFT trial for zoledronic acid 5 mg, and from meta-analyses from NICE reviews for generic alendronate, assumed to be equal to branded alendronate. Compliance with zoledronic acid was assumed to be 100% (by definition of a once-yearly infusion) and sensitivity analyses were conducted for the compliance with generic alendronate, with decreased efficacy extrapolated from the relationship between compliance and probability of fracture (Siris, 2006) . Costs of fractures were taken from Danish cost studies and/or DRG cost lists and pharmacy costs of the medications were based on official list prices. Utilities were obtained from the literature. RESULTS: For patients 70 years old with a T-score of 2.5, zoledronic acid dominated generic alenronate when compliance with generic alendronate was 70% or lower. The dominating cost effectiveness of zoledronic acid over generic alendronate increased with decreased generic alendronate compliance, with incremental cost effectiveness ratios (ICERs) of between 5.077 DKK for 70% compliance and 48,202 DKK for 50% compliance. CONCLUSIONS: A single annual infusion of zoledronic acid 5 mg provides cost savings over daily generic alendronate, assuming a conservative real-life compliance of 70% for generic alendronate. Therefore, despite the availability of cheaper generics, their poor compliance results in cost savings for a more expensive alternative with better compliance. Further data is needed to make conclusions on longer term implications.
PMS38 ECONOMIC ANALYSIS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP OR KNEE REPLACEMENT IN SPAIN
Gonzalez-Rojas N 1 , Vieta A 2 , Monreal M 3 , Wolowacz SE 4 1 Boehringer Ingelheim, Sant Cugat del Vallés, Barcelona, Spain, 2 IMS Health, Barcelona, Spain, 3 Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain, 4 RTI-Health Solutions, Manchester, UK OBJECTIVES: Evaluate the cost-effectiveness of dabigatran etexilate compared with enoxaparin for the primary prophylaxis of venous thromboembolism (VTE) after total hip replacement (THR) or total knee replacement (TKR) in Spain. METHODS: A published cost-effectiveness model was adapted to the perspective of the Spanish National Health Service. Oral dabigatran etexilate 220 mg/day was compared with injectable enoxaparin 40 mg/day. The efficacy and safety of the treatments was determined from two pivotal phase III studies comparing these interventions. The model combined a decision tree for the peri-operative period (acute phase, 10 weeks) with a Markov model for long-term events (chronic phase, 60 years). The treatment patterns, consumption of resources and costs were based on quantitative (databases, patient registries, official statistics) and qualitative (systematic literature review, expert surveys) data sources for Spain. Univariate deterministic and probabilistic sensitivity analyses were performed. RESULTS: The study results suggest that overall outcomes do not differ significantly between dabigatran etexilate and enoxaparin. Mean Life years were 0.018 and 0.020 higher for dabigatran patients undergoing THR and TKR respectively; mean QALYs were 0.013 and 0.015 higher respectively. Mean overall costs were lower for dabigatran patients by a189 and a53 respectively. In the probabilistic sensitivity analysis, dabigatran etexilate was dominant for most of the one thousand simulations in THR. The probability that dabigatran is cost-effective at a threshold of a30,000/QALY was 99% in THR and 87% in TKR. In the deterministic sensitivity analysis, dabigatran was dominant versus enoxaparin in all scenarios in both THR and TKR. CONCLUSIONS: From the viewpoint of the Spanish NHS, primary prophylaxis with dabigatran etexilate (220 mg/day orally) has a lower cost than enoxaparin (40 mg/day subcutaneously) after THR and TKR with a comparable efficacy and safety profile. The management of moderate to severe rheumatoid arthritis includes the use of biologic agents. Modelling allows simulation of complex biologic treatment strategies after an insufficient response (IR) to previous biologic agents. The objective is to assess the cost-effectiveness of various biologic treatment sequences over two years according to the Turkish health care system using a public payer perspective. METHODS: Six treatment strategies using three successive biologic agents [etanercept (ETA), adalimumab (ADA), infliximab (INF), abatacept (ABA) or rituximab (RTX)], were modelled based on Turkish medical practice. Effectiveness was derived from published evidence as expected number of days in low disease activity state (LDAS). Biologic treatment was maintained for achieving LDAS or switched at each six months in case of IR. Total medical costs were estimated per level of disease activity over 6 months. Extensive probabilistic sensitivity analysis was performed. RESULTS: Considering an IR to 1 anti-TNF agent, the sequence ETA-ABA-ADA was more efficacious and cost-effective (102 days in LDAS; 496 TL per day in LDAS) over 2 years than the sequence ETA-RTX-ADA (82 days in LDAS; 554 TL per day in LDAS or 81 days in LDAS; 563 TL / day in LDAS based on RTX current reimbursement status). Considering an IR after 2 anti-TNF agents, the sequences ETA-ADA-ABA and ETA-INF-ABA were more efficacious and cost-effective (64 days in LDAS for both; 841 and 826 TL / day in LDAS, respectively) over 2 years than a sequence of anti-TNF agents only (32 days in LDAS; 1480 TL per day in LDAS). CONCLUSIONS: These simulations suggest that over two years of therapy, sequences including abatacept after an IR to one anti-TNF agent are more efficacious and cost-effective vs. similar sequences including rituximab. Sequences including abatacept after an IR to 2 anti-TNF agents also appear more effective and cost-effective than similar sequences composed of anti-TNF agents only.
PMS39 SEQUENTIAL COST-EFFECTIVENESS MODELLING OF DIFFERENT BIOLOGIC STRATEGIES IN RHEUMATOID ARTHRITIS IN TURKEY

PMS40 COST-EFFECTIVENESS SIMULATION MODEL OF BIOLOGIC STRATEGIES FOR THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS BASED ON DISEASE ACTIVITY IN GERMANY
Beresniak A 1 , Baerwald C 2 , Zeidler H 3 , Gromnica-Ihle E 4 , Kruger K 5 , Neubauer AS 6 , Dupont D 7 , Merkesdal S 8
